The current evaluation of nonpalpable breast lesions.

Arch Surg

UAMS, Department of Surgery, Little Rock 72205.

Published: December 1987

To understand the suspected low yield of malignant neoplasms from biopsies guided by needle localization, we reviewed 122 biopsies performed from January 1985 to November 1986 at University Hospital and Arkansas Baptist Medical Center, Little Rock. The positive biopsy rates were 3.5% and 10.6%, respectively. After review of these cases, the following guidelines for biopsy were developed: (1) Do not perform a biopsy on a low-density mass less than 1 cm in diameter. (2) Do not perform a biopsy for asymmetric density or questionable mass. (3) Do not perform a biopsy for secondary signs of malignancy such as skin thickening or asymmetric vasculature. (4) Biopsy is indicated for clustered calcifications, a dominant mass greater than 1 cm in diameter, stellate lesions, or interval change from a previous mammogram. These changes resulted in a positive biopsy rate of 15% for the period from November 1986 through April 1987.

Download full-text PDF

Source
http://dx.doi.org/10.1001/archsurg.1987.01400240035005DOI Listing

Publication Analysis

Top Keywords

perform biopsy
12
november 1986
8
positive biopsy
8
biopsy
7
current evaluation
4
evaluation nonpalpable
4
nonpalpable breast
4
breast lesions
4
lesions understand
4
understand suspected
4

Similar Publications

Background: Radioactive iodine (RAI) is a common treatment for various thyroid diseases. Previous studies have suggested susceptibility of parathyroid glands to the mutagenic effect of RAI and the development of primary hyperparathyroidism (PHPT). We tested the possible link between prior RAI treatment, disease presentation, and treatment outcomes.

View Article and Find Full Text PDF

Introduction: Solitary plasmacytomas are tumors characterized by a local increase of malignant plasma cells in soft tissue or bone and may occur anywhere without evidence of systemic disease. The aim was to focus on the main surgical techniques and outcomes for this rare chest wall tumor.

Methods: Patients with solitary plasmacytoma involving a rib, who were operated for diagnostic or treatment purposes between 2018 and 2023 were retrospectively reviewed.

View Article and Find Full Text PDF

Background: Segmentation models for clinical data experience severe performance degradation when trained on a single client from one domain and distributed to other clients from different domain. Federated Learning (FL) provides a solution by enabling multi-party collaborative learning without compromising the confidentiality of clients' private data.

Methods: In this paper, we propose a cross-domain FL method for Weakly Supervised Semantic Segmentation (FL-W3S) of white blood cells in microscopic images.

View Article and Find Full Text PDF

Rare dual MYH9-ROS1 fusion variants in a patient with lung adenocarcinoma: A case report.

Medicine (Baltimore)

January 2025

Department of Respiratory and Critical Care Medicine, Zhongshan City People's Hospital, Zhongshan, Guangdong Province, China.

Rationale: ROS proto-oncogene 1 (ROS1) fusion is a rare but important driver mutation in non-small cell lung cancer, which usually shows significant sensitivity to small molecule tyrosine kinase inhibitors. With the widespread application of next-generation sequencing (NGS), more fusions and co-mutations of ROS1 have been discovered. Non-muscle myosin heavy chain 9 (MYH9) is a rare fusion partner of ROS1 gene as reported.

View Article and Find Full Text PDF

Chronic coronary artery disease (CAD) remains a significant global healthcare burden. Current risk assessment methods have notable limitations in early detection and risk stratification. Hence, there is an urgent need for innovative biomarkers that facilitate the premature CAD diagnosis, ultimately leading to reduction in associated morbidity and mortality rates.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!